REVBW News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

RE

Mkt Cap

N/A

Volume

15.49K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains—Intel, CSX In Focus (UPDATED)U.S. stock futures declined slightly on Friday after two consecutive days of gains, following President Trump's withdrawal of EU tariffs and better-than-expected Q3 GDP figures at 4.4%. Key movers include Intel down 12% on weak guidance, Capital One down 3.31% on earnings miss, Revelation Biosciences up 38% on FDA approval pathway, and CSX up 2.99% despite missing estimates. Bank of America's fund manager survey shows institutional investors at their most bullish since 2021.Benzinga · Jan 23, 2026

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate ProgressSAN DIEGO, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today reported its second quarter 2022 financial results and highlighted recent corporate progress.GlobeNewswire Inc. · Aug 15, 2022

Revelation Biosciences Inc. Announces Closing of $5 Million Public OfferingSAN DIEGO, July 29, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced the closing on July 28, 2022 of its previously announced public offering of 8,333,334 shares of its common stock, together with warrants to purchase up to 8,333,334 shares of its common stock at an offering price to the public of $0.60 per share and associated warrant. The warrants have an exercise price of $0.60 per share, are exercisable upon issuance, and will expire five years following the date of issuance.GlobeNewswire Inc. · Jul 29, 2022

Revelation Biosciences Inc. Announces Pricing of $5 Million Public OfferingSAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced the pricing of a public offering of 8,333,334 shares of its common stock, together with warrants to purchase up to 8,333,334 shares of its common stock at an offering price to the public of $0.60 per share and associated warrant. The warrants will have an exercise price of $0.60 per share, are exercisable upon issuance, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about July 28, 2022, subject to the satisfaction of customary closing conditions.GlobeNewswire Inc. · Jul 26, 2022

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic RhinitisSAN DIEGO, July 22, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced topline data for its Phase 1b CLEAR clinical study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhinitis to rye grass pollen.GlobeNewswire Inc. · Jul 22, 2022

Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis -Data anticipated in Q3 2022- -Data anticipated in Q3 2022-GlobeNewswire Inc. · Jun 13, 2022

Revelation Biosciences Raises $7.76 Million in Equity FinancingSAN DIEGO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that it has entered into a definitive agreement with a leading healthcare-focused institutional investor, pursuant to which the Company agreed to sell 1,293,126 shares of Common Stock (“Shares”) at a gross purchase price of $3.00 per Share. Additionally, Revelation has agreed to issue to the investor unregistered warrants to purchase up to 2,586,667 shares (the “Common Warrants”), as well as unregistered pre-funded warrants to purchase up to 1,239,541 shares (the “Pre-Funded Warrants” and together with the Common Warrants, the “Warrants”) in a concurrent private placement. The Common Warrants have an exercise price of $3.29 per share, will become exercisable in six months after their date of issuance and will expire five and a half years from their date of issuance. The Pre-Funded Warrants have been funded to the amount of $3.00 with $0.0001 payable on exercise.GlobeNewswire Inc. · Jan 24, 2022

REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed-GlobeNewswire Inc. · Jan 13, 2022

RE

REVBWRevelation Biosciences, Inc. Warrant

REVBW

Pay with—

Available Balance0.00

Your PositionYou don't own any REVBW yet.

Related Tickers

Earnings